Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults With Early Symptomatic Alzheimer's Disease

Next Previous
Search
Trial Profile

Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults With Early Symptomatic Alzheimer's Disease

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Donanemab (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Adverse reactions; Registrational
  • Acronyms TRAILBLAZER-ALZ 6
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 29 Oct 2024 According to Eli Lilly and Company media release, Lilly is discussing the results of this study with global regulators, with the intent to submit for a potential label update for Kisunla.
    • 29 Oct 2024 According to Eli Lilly and Company media release, data from the study were presented at the 17th Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain.
    • 29 Oct 2024 Results presented in the Eli Lilly and Company Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top